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Background
Study 903 was a Phase III randomized double-blind
(DB) 3 year study comparing TDF to stavudine (d4T)
each in combination with lamivudine (3TC) and efavir-
enz (EFV) in HIV-1 infected antiretroviral naïve
patients. TDF was associated with durable efficacy and
safety (better lipid profile, and less lipodystrophy and
peripheral neuropathy). A subset of these patients now
provides 10 years of longitudinal efficacy and safety data
of TDF-containing once-daily HAART.
Methods
Subjects in Argentina, Brazil, and the Dominican Repub-
lic who completed the 3 year DB period of study were
eligible to roll-over into an open-label (OL) study (Study
903E) of the once-daily HAART regimen, TDF+3TC
+EFV. At DB baseline 86 subjects were randomized to
TDF (62% male, 70% white, mean age 33 yrs, mean HIV
RNA=4.9 log10 c/mL, and mean CD4 count=299 cells/
mm
3). At OL baseline, 85 subjects (60% male, 64%
white, mean age 37 yrs, median CD4=621 cells/mm
3)
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Table 1
TDF/TDF
a (n=86) D4T/TDF
a (n=85)
Weeks on HAART/TDF 480/480 480/336
HIV RNA < 50 (copies/mL) at Week 480 (ITT, M=F) 63% 64%
HIV RNA < 50 (copies/mL) at Week 480 (ITT, M=E) 92% 96%
Change in Mean (SD) CD4, cells/mm
3 545 (287) 180 (290)
Drug-related Adverse Events (Grades 1-4) 66% 46%
Change in Mean (SD) Creatinine Clearance, mL/min
b +2.5 (23.4) -10.7 (22.6)
Median Limb Fat at Year 10, kg 10.4 7.5
Percent Change in Mean (SD) Spine BMD
c -2.44 (5.08)
δ 0.04 (4.72)
Percent Change in Mean (SD) Hip BMD -2.94 (4.95)
δ -1.86 (4.67)
δ
Discontinuations during open-label extension 25 (29.1%) 19 (22.4%)
Adverse event 2 (2.3%) 2 (2.4%)
Suboptimal virologic response 5 (5.8%) 1 (1.2%)
LTFU
ε, Nonadherent, Pregnancy, Consent Withdrawn, Death 13 (15.1%) 9 (10.6%)
Other 5 (5.8%) 7 (8.2%)
aTDF/TDF results measured from DB BL; d4T/TDF from OL baseline;
bEstimated by Cockcroft-Gault equation;
cBone mineral density;
δp<0.01 by Wilcoxon Signed
Rank Test;
εLost to follow-up
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period of TDF exposure.
Results
See Table 1
Conclusions
Antiretroviral-naïve subjects who received TDF-contain-
ing once-daily HAART for up to 10 years demonstrated
sustained virologic and immunologic benefit, improved
limb fat, stable renal function, and their BMD remained
stable after a clinically insignificant decrease that
occurred during the first year of TDF therapy.
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